vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CHIMERA INVESTMENT CORP (CIM). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $66.2M, roughly 1.3× CHIMERA INVESTMENT CORP). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs 6.8%, a 36.0% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 0.5%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
BLLN vs CIM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $66.2M |
| Net Profit | $5.7M | $28.3M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 42.6% |
| Net Margin | 6.8% | 42.8% |
| Revenue YoY | 117.4% | 0.5% |
| Net Profit YoY | 138.3% | 119.3% |
| EPS (diluted) | $0.10 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $66.2M | ||
| Q3 25 | $83.5M | $65.0M | ||
| Q2 25 | — | $66.0M | ||
| Q1 25 | — | $69.2M | ||
| Q4 24 | $45.1M | $65.8M | ||
| Q3 24 | $38.4M | $66.5M | ||
| Q2 24 | — | $67.3M | ||
| Q1 24 | — | $65.1M |
| Q4 25 | — | $28.3M | ||
| Q3 25 | $5.7M | $-580.0K | ||
| Q2 25 | — | $35.5M | ||
| Q1 25 | — | $167.3M | ||
| Q4 24 | $-11.5M | $-146.5M | ||
| Q3 24 | $-14.9M | $136.5M | ||
| Q2 24 | — | $56.7M | ||
| Q1 24 | — | $129.5M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 42.6% | ||
| Q3 25 | 11.5% | -0.5% | ||
| Q2 25 | — | 54.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | 17.0% | -222.6% | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | 84.2% | ||
| Q1 24 | — | — |
| Q4 25 | — | 42.8% | ||
| Q3 25 | 6.8% | -0.9% | ||
| Q2 25 | — | 53.7% | ||
| Q1 25 | — | 241.7% | ||
| Q4 24 | -25.5% | -222.6% | ||
| Q3 24 | -38.8% | 205.4% | ||
| Q2 24 | — | 84.2% | ||
| Q1 24 | — | 198.8% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.10 | $-0.27 | ||
| Q2 25 | — | $0.17 | ||
| Q1 25 | — | $1.77 | ||
| Q4 24 | $-1.13 | $-2.06 | ||
| Q3 24 | $-1.47 | $1.39 | ||
| Q2 24 | — | $0.41 | ||
| Q1 24 | — | $1.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $278.6M |
| Total DebtLower is stronger | $55.0M | $251.5M |
| Stockholders' EquityBook value | $-239.5M | $2.6B |
| Total Assets | $327.5M | $15.8B |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $278.6M | ||
| Q3 25 | $195.2M | $491.5M | ||
| Q2 25 | — | $250.2M | ||
| Q1 25 | — | $253.3M | ||
| Q4 24 | $191.5M | $84.0M | ||
| Q3 24 | — | $97.3M | ||
| Q2 24 | — | $162.3M | ||
| Q1 24 | — | $169.0M |
| Q4 25 | — | $251.5M | ||
| Q3 25 | $55.0M | $251.0M | ||
| Q2 25 | — | $135.2M | ||
| Q1 25 | — | $134.9M | ||
| Q4 24 | $51.5M | $134.6M | ||
| Q3 24 | — | $134.4M | ||
| Q2 24 | — | $62.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | $2.6B | ||
| Q3 25 | $-239.5M | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | $-251.7M | $2.5B | ||
| Q3 24 | $-242.9M | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | $15.8B | ||
| Q3 25 | $327.5M | $15.1B | ||
| Q2 25 | — | $14.9B | ||
| Q1 25 | — | $13.2B | ||
| Q4 24 | $302.1M | $13.1B | ||
| Q3 24 | — | $13.7B | ||
| Q2 24 | — | $13.1B | ||
| Q1 24 | — | $12.5B |
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-248.9M |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | -8.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-248.9M | ||
| Q3 25 | $13.8M | $-137.5M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $48.8M | ||
| Q4 24 | — | $205.7M | ||
| Q3 24 | — | $41.4M | ||
| Q2 24 | — | $69.0M | ||
| Q1 24 | — | $57.3M |
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -8.78× | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | -0.21× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | 0.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CIM
Segment breakdown not available.
